6,9-二氯-2-甲氧基吖啶 | 86-38-4

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6,9-二氯-2-甲氧基吖啶
• 英文名称: 6,9-dichloro-2-methoxyacridine
• 英文别名: 2-methoxy-6,9-dichloroacridine
• CAS: 86-38-4
• 化学式: C₁₄H₉Cl₂NO
• mdl: MFCD00005028
• 分子量: 278.138
• InChiKey: RYRNQWYNHLLOGX-UHFFFAOYSA-N

物化性质

• 熔点：
  163-165 °C (lit.)
• 沸点：
  444.3±25.0 °C(Predicted)
• 密度：
  1.52 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38,R42/43
• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险标志：
  GHS07,GHS08
• 危险性描述：
  H315,H317,H319,H334,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338,P342 + P311
• 储存条件：
  2-8°C

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 6,9-Dichloro-2-methoxyacridine
CAS-No. : 86-38-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Respiratory sensitization (Category 1)
Skin sensitization (Category 1)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin. May cause sensitization by inhalation and skin contact.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust.
P280 Wear protective gloves.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
R42/43 May cause sensitization by inhalation and skin contact.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S37/39 Wear suitable gloves and eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C14H9Cl2NO
Molecular Weight : 278,13 g/mol
Component Concentration
3,9-Dichloro-7-methoxyacridine
CAS-No. 86-38-4 -
EC-No. 201-666-7

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Conjunctivitis., Dermatitis, To the best of our knowledge, the chemical, physical, and toxicological
properties have not been thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 163 - 165 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
May cause allergic respiratory and skin reactions
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
Conjunctivitis., Dermatitis, To the best of our knowledge, the chemical, physical, and toxicological
properties have not been thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：针状结晶，熔点为160-161℃（亦可参考163-165℃）。它尚易溶于醇、苯和甲苯，稍溶于醚和酮。

用途：主要用作医药中间体。

生产方法：由2,4-二氯甲苯经氧化、缩合、酸化、环合及氯化而制得。

反应信息

• 作为反应物：
  描述：

  6,9-二氯-2-甲氧基吖啶 在 盐酸 作用下， 反应 2.0h， 以0.9 g的产率得到6-chloro-2-methoxyacridone
  参考文献：
  名称：

  2-羟基和2-甲氧基取代吖啶的区域选择性亲电取代。在吡啶并[2,3,4-mn]吖啶合成中的应用

  摘要：

  摘要 吖啶2 位羟基或甲氧基的存在使甲磺酸中的甲醛发生亲电取代反应到1 位。该反应用于合成吡啶并[2,3,4-m,n]吖啶。

  DOI：

  10.1080/00397919708003387
• 作为产物：
  描述：

  2,4-二氯苯甲酸 在 铜 、 potassium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 6,9-二氯-2-甲氧基吖啶
  参考文献：
  名称：

  探索cr啶支架作为发现新型多靶标VEGFR-2和Src激酶抑制剂的潜在有趣支架

  摘要：

  VEGFR-2和Src激酶均在癌症中发挥重要作用。在某些癌症中，Src与VEGFR-2协同作用以促进其激活。针对VEGFR-2和Src的多靶点药物的开发具有针对这些癌症的治疗优势。通过使用分子对接和SVM虚拟筛选方法，并基于随后的合成和生物测定研究，我们确定了带有an啶支架的9-氨基ac啶衍生物可能是有趣的新型VEGFR-2和Src双重抑制剂。cr啶支架在历史上一直用于衍生拓扑异构酶抑制剂，但在现有的VEGFR-2抑制剂和Src抑制剂中尚未发现。合成了一系列21种a啶衍生物，并评估了其对K562，HepG-2和MCF-7细胞的抗增殖活性。这些化合物中的一些在体外显示出比伊马替尼更好的抗K562细胞活性。分析了这些化合物的构效关系（SAR）。化合物之一（7r）显示出对K562和HepG-2癌细胞系的低μM活性，并且在50μM下分别以44％和8％的抑制率抑制了VEGFR-2和Src，而没有抑制

  DOI：

  10.1016/j.bmc.2011.04.053

文献信息

• Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives
  作者：Sandra Gemma、Gagan Kukreja、Pierangela Tripaldi、Maria Altarelli、Matteo Bernetti、Silvia Franceschini、Luisa Savini、Giuseppe Campiani、Caterina Fattorusso、Stefania Butini

  DOI：10.1016/j.tetlet.2008.01.128

  日期：2008.3

  Nickel(II) chloride/sodium borohydride combination was employed for the reduction of 4-hydrazinoquinoline derivatives to the corresponding anilines. This reductive protocol was efficiently applied for the reductive cleavage of monosubstituted hydrazines. We described herein the microwave-assisted synthesis of 4-hydrazinoquinolines, which furnished a high yielding and rapid two-step procedure for the

  氯化镍（II）/硼氢化钠组合用于将4-肼基喹啉衍生物还原为相应的苯胺。该还原方案被有效地应用于单取代肼的还原裂解。我们在本文中描述了4-肼基喹啉的微波辅助合成，其提供了高产率和快速的两步法，用于在温和条件下合成4-氨基喹啉作为抗疟原体。
• [EN] COMPOUNDS WITH ANTIMALARIAL ACTIVITY<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ ANTIPALUDÉENNE
  申请人：UNIV DEGLI STUDI MILANO

  公开号：WO2010034512A1

  公开（公告）日：2010-04-01

  New usnic acid derivatives, conjugation products of usnic acid with biologically active molecules and pharmaceutical compositions thereof are described, which are useful for the prophylaxis and therapy of infections from protozoa of the Plasmodium genus.

  新的乌司酸衍生物，乌司酸与生物活性分子的共轭产物以及其制药组合物被描述，这些物质对于原生动物寄生虫Plasmodium属的感染的预防和治疗是有用的。
• Linker-modified triamine-linked acridine dimers: Synthesis and cytotoxicity properties in vitro and in vivo
  作者：Shan-Shue Wang、Yi-Jen Lee、Shih-Chung Hsu、Hsueh-O Chang、Wei-Kung Yin、Lien-Shange Chang、Shan-Yen Chou

  DOI：10.1016/j.bmc.2006.10.054

  日期：2007.1

  preparation and cytotoxicity properties of a series of N(epsilon)-substituted triamine-linked acridine dimers are described. Most acridine dimer derivatives reveal highly potent in vitro cytotoxicity properties and DNA binding activity. Several acridine dimers were selected to study their action in vivo. These acridine dimers have demonstrated a narrow safe margin, as has adriamycin, but higher maximum

  描述了一系列N（ε）取代的三胺连接的a啶二聚体的制备和细胞毒性。大多数a啶二聚体衍生物具有很强的体外细胞毒性和DNA结合活性。选择了几种a啶二聚体以研究其在体内的作用。与阿霉素相比，这些demonstrated啶二聚体已显示出狭窄的安全范围，但与ICR小鼠中的阿霉素相比，其最大耐受剂量（MTD）更高。cr啶二聚体在体内还表现出各种抗anol-COLO 205实体肿瘤活性。化合物1显示出最有效的实体瘤抑制作用。
• In vitro efficiency of new acridyl derivatives against Plasmodium falciparum
  作者：Lucie Guetzoyan、Florence Ramiandrasoa、Hélène Dorizon、Christine Desprez、Alexandre Bridoux、Christophe Rogier、Bruno Pradines、Martine Perrée-Fauvet

  DOI：10.1016/j.bmc.2007.02.022

  日期：2007.5

  A series of new 9-substituted acridyl derivatives were synthesized and their in vitro antimalarial activity was evaluated against one chloroquine-sensitive strain (3D7) and three chloroquine-resistant strains [W2 (Indochina), Bre1 (Brazil) and FCR3 (Gambia)] of Plasmodium falciparum. Some compounds inhibit the growth of malarial parasite with IC50

  合成了一系列新的9-取代的cri啶衍生物，并评估了它们对一种对氯喹敏感的菌株（3D7）和三种对氯喹耐药的菌株[W2（印度支那），Bre1（巴西）和FCR3（冈比亚）]的体外抗疟活性。恶性疟原虫。一些化合物通过IC50抑制疟疾寄生虫的生长
• Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents
  作者：Bin Zhang、Zhende Dou、Zheng Xiong、Ning Wang、Shan He、Xiaojun Yan、Haixiao Jin

  DOI：10.1016/j.bmcl.2019.126714

  日期：2019.12

  inhibition, western blot assay and cell apoptosis detection. In summary, 9b effectively inhibited the activity of Topo I/II and induced DNA damage in CCRF-CEM cells and, moreover, significantly induced cell apoptosis in a concentration-dependent manner. These observations provide new information and guidance for the structural optimization of more novel acridine derivatives.

  最初基于氨苯磺酸（m -AMSA）的结构设计和合成了一系列新型的N-苯基苯甲酰胺-4-甲胺a啶衍生物。分子对接表明，代表性化合物9a具有与DNA拓扑异构酶（Topo）II结合的亲和力，与m -AMSA相当，而且9a可以与Topo I发生优先相互作用。合成9a和类似物9b - 9f之后，这些都在体外进行了测试合成的化合物对三种不同的癌细胞系（K562，CCRF-CEM和U937）具有有效的抗增殖活性。其中，化合物9b，9c和9d对CCRF-CEM细胞表现出最高的活性，IC 50值为0.82至0.91μM。此外，9b和9d还显示出对U937细胞的高抗增殖活性，IC 50值分别为0.33和0.23μM。通过Topo I / II抑制，蛋白质印迹分析和细胞凋亡检测评估了这些化合物的药理学机理。综上所述，9b在CCRF-CEM细胞中有效抑制Topo I / II的活性并诱导DNA损伤，此外，以浓度依

表征谱图